Skip to content
WrothamPartners

Sector

HealthTech

Digital health, clinical software and life-science technology businesses.

Overview

Healthcare technology combines long procurement cycles with unusually durable contracts. Investor conviction depends on evidence, reimbursement pathways and a realistic view of how quickly institutions adopt.

Market perspective

How capital is approaching the sector.

Clinical evidence and health-economic outcomes carry weight that no commercial narrative can substitute for. Where they exist, they materially change how a business is valued.

Procurement realities differ across health systems in Europe, and a plan that works in one market often needs rebuilding for the next. Investors test this closely.

Life-science tooling and informatics attract a distinct investor base that is comfortable with longer horizons and more technical diligence.

Areas of focus

  • Clinical and care-delivery software
  • Diagnostics and decision support
  • Life-science tooling and informatics
  • Payer and provider infrastructure
  • Patient engagement and remote care

The investor lens

  • Clinical and economic evidence
  • Reimbursement and procurement pathway
  • Contract length and renewal behaviour
  • Regulatory classification
  • Sales cycle and implementation cost

Capital considerations

Matching the business to the capital.

Capital ranges from generalist growth investors to healthcare specialists and strategic parties. Alignment on time horizon is more important in this sector than in most.

The practical consequence for management teams is that the choice of capital provider is a strategic decision in its own right. Expectations on pace, governance, reporting and horizon vary considerably between pools of capital that appear interchangeable from the outside.

Discuss your capital strategy.

A confidential conversation about objectives, timing and the options available.